What is the role of delafloxacin (Baxdela) in the empiric treatment of community-acquired pneumonia (CAP)?

Updated: Jul 22, 2021
  • Author: Folusakin O Ayoade, MD; Chief Editor: Thomas E Herchline, MD  more...
  • Print
Answer

Answer

Delafloxacin (Baxdela), a fluoroquinolone, gained approval in October 2019 for the treatment of bacterial CAP in adults. Approval was based on a phase 3 randomized, double-blind study (n = 859) that compared delafloxacin to moxifloxacin. Results showed that IV-to-oral delafloxacin was noninferior at 96 hours compared with moxifloxacin. [11, 12]

Dosing for delafloxacin is as follows:

  • 300 mg IV q12hr for 5-10 days  or
  • 300 mg IV q12hr, then switch to a 450-mg tablet PO q12hr for 5-10 days  or
  • 450 mg PO q12hr for 5-10 days

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!